Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101985 · ClinicalTrials.gov registry record · Phase 2
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
A Phase 2 study of Irritable Colon, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 741
- Enrollment target
- 20
- Study locations
NCT00101985: Completed Phase 2 study of Irritable Colon, sponsored by GlaxoSmithKline.
NCT00101985 is a Phase 2 study of Irritable Colon that has completed, run by GlaxoSmithKline. The registered enrollment target is 741 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (457% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101985, a Phase 2 study of Irritable Colon, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 741 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).
Conditions Studied
Interventions
- DRUG talnetant
Study Locations (20)
California
- GSK Investigational Site - Carmichael
- GSK Investigational Site - Concord
- GSK Investigational Site - Garden Grove
- GSK Investigational Site - Orange
- GSK Investigational Site - Roseville
- GSK Investigational Site - Spring Valley
- GSK Investigational Site - Torrance
Colorado
- GSK Investigational Site - Boulder
- GSK Investigational Site - Centennial
- GSK Investigational Site - Wheat Ridge
Connecticut
- GSK Investigational Site - Bristol
- GSK Investigational Site - Stamford
- GSK Investigational Site - Torrington
Florida
- GSK Investigational Site - DeLand
- GSK Investigational Site - Miami
- GSK Investigational Site - St. Petersburg
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Phoenix
Arkansas
- GSK Investigational Site - North Little Rock
Delaware
- GSK Investigational Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00101985 record still lists
NCT00101985 is an interventional study that assigns participants to a tested intervention. The registered 741 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (457% higher).
The record links to 1 condition, with Irritable Colon appearing as the primary indexed condition, and to 1 intervention - of which talnetant is the first listed.
NCT00101985 names 20 study sites across 7 states, led by California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00101985 about?
NCT00101985 is a clinical study titled "Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)". This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).
What is the current status of trial NCT00101985?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 741 participants. The study started on 2004-10. Estimated completion is 2005-07.
What conditions does trial NCT00101985 study?
This clinical trial studies the following conditions: Irritable Colon.
What interventions are being tested in trial NCT00101985?
The interventions under investigation include: talnetant (DRUG).
Who is sponsoring clinical trial NCT00101985?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00101985 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Colon
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00101985's enrollment target sits among peer trials
741 44th of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia